At the 2025 Annual General Meeting of Shareholders (AGM), Imexpharm approved its 2025 growth plan, targeting total revenue of VND 2,981 billion and profit before tax of VND 493.5 billion - representing year-on-year increases of 18.6% and 22.1%, respectively.